Literature DB >> 3756799

The correlation of pretreatment transurethral resection of prostatic cancer with tumor dissemination and disease-free survival. A univariate and multivariate analysis.

J D Forman, S E Order, E S Zinreich, D J Lee, M D Wharam, E D Mellits.   

Abstract

A multivariate Cox's hazard function analysis was performed on the prognostic variables selected from 240 patients with localized carcinoma of the prostate who received external beam radiotherapy to analyze the association between the method of biopsy and disease-free survival. The patients received 4500 cGy to the pelvis followed by a 2-week treatment rest and then an additional 2000 cGy to the reduced prostatic volume. Median follow-up was 4 years (range, 1-9 years). The 5-year actuarial local control rate was 91%. There was no difference in local control relative to the method of biopsy (needle biopsy or transurethral resection of the prostate [TURP]). The 5-year actuarial risks of metastases were 28% and 48% for the needle biopsy and TURP groups, respectively (P less than 0.01). The 5-year disease-free survival for the needle biopsy and TURP groups were 55% and 42%, respectively (P less than 0.05). This difference maintained statistical significance for Stage C and Grade III tumors. A multivariate analysis demonstrated that "method of biopsy" was the third most powerful variable after serum acid phosphatase level and modified Broders' grade in predicting disease-free survival. Patients who had TURP had an almost twofold higher relative risk of disease progression than those who had needle biopsy. This study established the correlation of the method of biopsy with a lower probability of disease-free survival over and above the information obtained from the clinical stage, histologic grade, presence or absence of symptoms of obstruction, acid phosphatase level, and lymph node status. The association of TURP with tumor dissemination is discussed with reference to the mechanism of metastasis formation and prevention.

Entities:  

Mesh:

Year:  1986        PMID: 3756799     DOI: 10.1002/1097-0142(19861015)58:8<1770::aid-cncr2820580832>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.

Authors:  Tracey L Krupski; George J Stukenborg; Kihyuck Moon; Dan Theodorescu
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

Review 2.  The problem of obstruction in prostate cancer.

Authors:  H P Schmid
Journal:  Urol Res       Date:  1991

3.  Effects of pretreatment transurethral resection on survival in prostatic carcinoma.

Authors:  J P Austin; H Aziz; L Potters; J Oshelfski; K Choi; M Rotman
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

Review 4.  Managing the local complications of locally advanced prostate cancer.

Authors:  Jason W Anast; Gerald L Andriole; Robert L Grubb
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

5.  Placement of retrievable self-expandable metallic stents with barbs into patients with obstructive prostate cancer.

Authors:  Ho-Young Song; Choung Soo Kim; In Gab Jeong; Dalsan Yoo; Jin Hyoung Kim; Deok Ho Nam; Jae-Ik Bae; Jung-Hoon Park
Journal:  Eur Radiol       Date:  2012-09-16       Impact factor: 5.315

6.  Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study.

Authors:  Se Young Choi; Jeman Ryu; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-07       Impact factor: 4.553

7.  Bipolar versus monopolar technique for palliative transurethral prostate resection.

Authors:  Dirk P J Michielsen; Danny Coomans; Benedikt Engels; Johan G Braeckman
Journal:  Arch Med Sci       Date:  2010-10-26       Impact factor: 3.318

8.  Pulmonary metastases after low-dose-rate brachytherapy for localized prostate cancer.

Authors:  Masahito Kido; Hidetoshi Kuruma; Hiroshi Sasaki; Kenta Miki; Manabu Aoki; Takahiro Kimura; Hiroyuki Takahash; Chihiro Kanehira; Shin Egawa
Journal:  Korean J Urol       Date:  2014-05-12

9.  Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.

Authors:  Diletta Bianchini; David Lorente; Pasquale Rescigno; Zafeiris Zafeiriou; Elena Psychopaida; Hazel O'Sullivan; Mervyn Alaras; Michael Kolinsky; Semini Sumanasuriya; Mariane Sousa Fontes; Joaquin Mateo; Raquel Perez Lopez; Nina Tunariu; Nikolaos Fotiadis; Pardeep Kumar; Alison Tree; Nicholas Van As; Vincent Khoo; Chris Parker; Rosalind Eeles; Alan Thompson; David Dearnaley; Johann S de Bono
Journal:  Clin Genitourin Cancer       Date:  2017-04-26       Impact factor: 2.872

10.  Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy.

Authors:  A E Bogden; D LePage; S Zwicker; W Grant; M Silver
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.